EWA
ZSAN

Exencial Wealth Advisors’s Zosano Pharma Corporation ZSAN Stock Holding History

Exencial Wealth Advisors’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-457
Closed -$34K – 233
2018
Q4 		$34K Buy
+457
New +$57.9K 0.01% 211

Other funds holding ZSAN

ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Exencial Wealth Advisors's ZSAN Position: Q1 2019 in Review

Exencial Wealth Advisors sold out of Zosano Pharma Corporation (ZSAN) in Q1 2019, closing a stake of 457 shares — an estimated $34K sold.

Exencial Wealth Advisors first reported a position in ZSAN in Q4 2018 and held it in 1 quarter. The position peaked at $34K in Q4 2018. 19 funds tracked by Wall St. Rank hold ZSAN as of Q1 2019.

  • Exencial Wealth Advisors reported no remaining Zosano Pharma Corporation position as of Q1 2019 after selling out during the quarter.
  • Exencial Wealth Advisors sold 457 Zosano Pharma Corporation shares in Q1 2019, an estimated $34K.
  • Exencial Wealth Advisors first reported a position in Zosano Pharma Corporation in Q4 2018 and held it in 1 quarter.
  • Exencial Wealth Advisors's Zosano Pharma Corporation position peaked at $34K in Q4 2018.
  • 19 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q1 2019.

Based on Exencial Wealth Advisors's 13F filing for Q1 2019, filed 8 May 2019.